Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples

Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertini...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Sci
Asıl Yazarlar: Kiura, Katsuyuki, Yoh, Kiyotaka, Katakami, Nobuyuki, Nogami, Naoyuki, Kasahara, Kazuo, Takahashi, Toshiaki, Okamoto, Isamu, Cantarini, Mireille, Hodge, Rachel, Uchida, Hirohiko
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891183/
https://ncbi.nlm.nih.gov/pubmed/29363250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13511
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller